|
| 37403432 | Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data. | Am J Hematol | 2023 |
| 37403432 | Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data. | Am J Hematol | 2023 |
| 37533343 | Epidemiology and clinical outcomes of light-chain amyloidosis in Sweden: A nationwide population-based study. | Eur J Haematol | 2023 |
| 37533343 | Epidemiology and clinical outcomes of light-chain amyloidosis in Sweden: A nationwide population-based study. | Eur J Haematol | 2023 |
| 35000586 | Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016. | BMC Res Notes | 2022 |
| 35000586 | Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016. | BMC Res Notes | 2022 |
| 33367863 | Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. | Rheumatology (Oxford) | 2021 |
| 34272262 | Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 34137077 | Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. | Eur J Haematol | 2021 |
| 33367863 | Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. | Rheumatology (Oxford) | 2021 |
| 34272262 | Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 34137077 | Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. | Eur J Haematol | 2021 |
| 32338068 | Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. | Curr Med Res Opin | 2020 |
| 32338068 | Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. | Curr Med Res Opin | 2020 |
| 32864627 | Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. | Lancet Rheumatol | 2020 |
| 32864627 | Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. | Lancet Rheumatol | 2020 |
| 30548238 | Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes. | Cancer | 2019 |
| 30548238 | Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes. | Cancer | 2019 |
| 31456304 | Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. | Pharmacoepidemiol Drug Saf | 2019 |
| 30789540 | Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients. | Med Care | 2019 |
| 31456304 | Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. | Pharmacoepidemiol Drug Saf | 2019 |
| 30789540 | Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients. | Med Care | 2019 |
| 28916489 | Reply to: comparative effectiveness medicines research cannot assess efficacy. | J Clin Epidemiol | 2017 |
| 28916489 | Reply to: comparative effectiveness medicines research cannot assess efficacy. | J Clin Epidemiol | 2017 |
| 28188899 | Publication of comparative effectiveness research has not increased in high-impact medical journals, 2004-2013. | J Clin Epidemiol | 2017 |
| 28188899 | Publication of comparative effectiveness research has not increased in high-impact medical journals, 2004-2013. | J Clin Epidemiol | 2017 |
| 26830509 | Applying the Social Ecological Model to Creating Asthma-Friendly Schools in Louisiana. | J Sch Health | 2016 |
| 28824834 | Methodologic Issues When Estimating Risks in Pharmacoepidemiology. | Curr Epidemiol Rep | 2016 |
| 26830509 | Applying the Social Ecological Model to Creating Asthma-Friendly Schools in Louisiana. | J Sch Health | 2016 |
| 28824834 | Methodologic Issues When Estimating Risks in Pharmacoepidemiology. | Curr Epidemiol Rep | 2016 |
| 24261517 | Roles of the state asthma program in implementing multicomponent, school-based asthma interventions. | J Sch Health | 2013 |
| 24261517 | Roles of the state asthma program in implementing multicomponent, school-based asthma interventions. | J Sch Health | 2013 |